Transporter-mediated GABA release induced by excitatory amino acid agonist is associated with GAD-67 but not GAD-65 immunoreactive cells of the primate retina.
The release of GABA from amacrine and interplexiform cells after exposure to excitatory amino acids (EAAs) agonists was investigated by immunohistochemistry. Cebus monkey retinas were treated in vitro with 50 microM kainate (KA) or 5 mM L-Glutamate (L-Glu), for 30 min at 37 degrees C. The effects of the EAAs were measured by detecting immunocytochemically the GABA remaining in the tissue after stimulation. L-Glu and KA reduced the number of GABA-immunoreactive perikarya in the innermost part of the inner nuclear layer by approximately 60% and 80%, respectively, as compared to controls. The cell processes in the inner plexiform layer (IPL) were restricted to only three defined bands in the strata 1, 3 and 5, as compared to an intense and homogeneous labeling in the IPL of the untreated retinas. The effect of KA was inhibited by 100 microM CNQX, 100 microM NNC-711, or when Na(+) was replaced by choline. The release of GABA was Ca(2+)-independent, suggesting the mobilization of GABA from the cytoplasmic pool of this neurotransmitter. At least two subsets of retinal neurons including amacrine and interplexiform cells retained GABA-immunoreactivity after stimulation with EAAs, as revealed by glutamic acid decarboxylase (GAD) immunocytochemistry. Our results suggest that non-NMDA receptor activation by KA and glutamate are associated with the efflux of GABA from cells of the inner retina (amacrine and interplexiform cells). The data also show that cells containing GAD-67 released GABA via its transporter, while cells containing exclusively GAD-65 apparently did not release the neurotransmitter by the reversal of the transporter.
Andrade da Costa
B L
BL
Departamento de Fisiologia e Farmacologia, UFPE, Recife, Brazil.
de Mello
F G
FG
Hokoç
J N
JN
D000818:Animals; D002118:Calcium / Q000494:pharmacology; D002352:Carrier Proteins / Q000187:drug effects* / Q000378:metabolism*; D002428:Cebus; D002452:Cell Count; D002478:Cells, Cultured; D018690:Excitatory Amino Acid Agonists / Q000494:pharmacology*; D005968:Glutamate Decarboxylase / Q000378:metabolism*; D018698:Glutamic Acid / Q000494:pharmacology; D007150:Immunohistochemistry; D007527:Isoenzymes / Q000378:metabolism*; D007608:Kainic Acid / Q000494:pharmacology; D009474:Neurons / Q000166:cytology / Q000187:drug effects* / Q000201:enzymology*; D012160:Retina / Q000166:cytology / Q000187:drug effects* / Q000201:enzymology*; D012964:Sodium / Q000494:pharmacology; D005680:gamma-Aminobutyric Acid / Q000378:metabolism*
D002352:Carrier Proteins; D018690:Excitatory Amino Acid Agonists; D007527:Isoenzymes; D018698:Glutamic Acid; D005680:gamma-Aminobutyric Acid; D012964:Sodium; D005968:Glutamate Decarboxylase; C402565:glutamate decarboxylase 1; C401141:glutamate decarboxylase 2; D007608:Kainic Acid; D002118:Calcium